Chinese vaccine for COVID-19 shows 79.34% effectiveness in late stage trial

Beijing, A Chinese inactivated vaccine shows 79.34 percent efficacy against COVID-19, according to the interim results of the phase-3 clinical trials unveiled by its developer on Wednesday.

The inactivated vaccine has been developed by the Beijing Biological Products Institute Co., Ltd. under the China National Biotec Group (CNBG), which is affiliated to Sinopharm, Xinhua news agency reported.

After a two-dose inoculation procedure, the vaccine receivers all produced high titers of antibodies, and the seroconversion rate of neutralising antibodies reached 99.52 percent.

The results meet the requirements of technical standards of the World Health Organization and the standards stipulated by China's National Medical Products Administration (NMPA).

The company has submitted an application to the Chinese regulator for conditional market approval.


SEE ALSO:
Top stocks to watch — SBI, HDFC Bank, Wipro, RIL, Future Retail, TCS, Jindal Stainless, UPL, IRCTC, and others
India detects 14 new cases of UK COVID-19 strain, putting the tally at 20India detects 14 new cases of UK COVID-19 strain, putting the tally at 20
2021 could finally be the year of India’s tech IPOs as startups like Zomato, Delhivery, Policybazaar head for the public markets